SMTI · Sanara MedTech

The thesis

Sanara MedTech's shares are more likely to lag the S&P 500 over three months. The sale to MiMedx has no closing date after the Federal Trade Commission (FTC) issued Second Requests to both companies on 15 October 2026, and Sanara's 12 November 2026 guidance cut lowers the value of the standalone business if the deal fails. The end of the FTC review, by clearance or challenge, settles the case.

The agreement pays $33.00 in cash plus 0.4735 MiMedx shares per eligible Sanara share, announced on 29 July 2026 as about $35 per share. Sanara closed at $32.54 on 12 November 2026, below the $33.00 cash portion alone. Shareholders approved the merger on 30 September 2026, so the open question is regulatory timing.

On 12 November 2026 Sanara reported third-quarter 2026 revenue of $28.4 million, up 8% from $26.3 million a year earlier, and cut 2026 revenue guidance to $110–115 million from $116–121 million. The release did not mention the FTC or give a closing timeline.

Bullish and bearish views on Sanara MedTech Inc.

The bull case on Sanara MedTech Inc. (SMTI), in brief: shareholders already approved the merger. The bear case: the FTC asked for more documents.

Bull case

• Shareholders already approved the merger. At the 30 September 2026 special meeting, 6,372,989 shares voted for, 1,944 against and 36,494 abstained. Shareholder rejection is no longer a risk.
• Both companies say they are working with the FTC. In its 28 October 2026 third-quarter release, MiMedx's chief executive said the company is working diligently with the FTC to obtain Hart-Scott-Rodino (HSR) clearance. Sanara's chief executive said on 12 November 2026 that the company continues to work through the regulatory and review process.
• Financing is committed. The 29 July 2026 announcement identifies a $300 million term-loan commitment from Hayfin Capital Management, and the merger agreement has no financing condition.
• The agreement runs well past year-end. The outside date is 29 July 2027, extendable to 29 January 2028 while antitrust approval is pending. A Second Request lengthens the review but does not end the agreement.
• Operating profit stayed positive before deal costs. Third-quarter adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, adjusted) was $5.6 million, up from $4.9 million a year earlier, per Sanara's 12 November 2026 release.

Bear case

• The FTC asked for more documents. The Second Request, received 15 October 2026, extends the HSR waiting period until 30 days after the parties substantially comply. Neither company's latest release gives a closing date.
• The shares trade below the cash portion. The 12 November 2026 close of $32.54 is under the $33.00 cash component. A discount to cash alone shows the market assigns real weight to delay or failure.
• Standalone guidance was cut. Sanara lowered 2026 revenue guidance on 12 November 2026 to $110–115 million, growth of about 7% to 12% over 2025 revenue of $103.1 million. A terminated deal returns the shares to this lower base.
• Third-quarter results showed a loss. Sanara reported a loss from continuing operations of $1.3 million, or $0.15 per diluted share, against income of $0.09 per share a year earlier. Merger-related legal and advisory costs were about $3.0 million in the quarter.
• The acquirer reported weaker results. MiMedx's third-quarter 2026 net sales were $62 million, down 45% from $114 million a year earlier, with wound sales down 71% to about $22 million, per its 28 October 2026 release. The 0.4735-share stock portion has no disclosed collar, so the value of the offer moves with MiMedx shares.
• The balance sheet is leveraged. Sanara held $16.8 million of cash and $46.7 million of long-term debt at 30 September 2026, per its 10-Q period data.

Price setup

Sanara closed at $32.54 on 12 November 2026. That is 8.4% below the 52-week intraday high of $35.52 set on 15 October 2026, the day the FTC issued the Second Request. The 3-month change is –4.7%, measured from the $34.15 close of 14 August 2026.

The 50-day average is $34.02 and the 200-day average is $25.93, both as of the 12 November 2026 close. The shares sit under the first and well above the second. The 52-week closing low is $16.34 on 25 March 2026, before the merger was announced.

Closes from 5 November to 12 November 2026 ranged between $31.55 and $32.54. The $33.00 cash portion is the nearest reference level, and the shares have not closed above it in that span. Merger-linked shares of this kind trade on completion odds and timing, so the price tracks the FTC process and MiMedx's share price more than Sanara's operating results.

The latest Form 4 on file is from 16 September 2026, when Chief Executive Seth Yon had 3,661 shares withheld for tax at $35.11. That is a tax withholding, not an open-market sale.

Catalysts ahead

• 29 July 2027: Contractual outside date of the MiMedx merger agreement, extendable to 29 January 2028 if antitrust approval is pending. Sets the latest date by which the FTC review must end before either side can walk away, and bounds how long the shares can trade on timing risk.
• ~31 December 2026 (est.): Company-stated year-end 2026 target for closing the merger; no revised target has been disclosed. The Second Request makes a year-end close harder; a revised timetable in a company filing would reset the window.

What would change the view

A daily close above $35.72, over the 52-week intraday high of $35.52, which would show the shares leading the S&P 500 as the market prices completion. An announced end to the FTC review with a closing date would also show the shares leading.

What it trades with

Sanara trades with MiMedx shares, because the 0.4735-share stock portion floats until closing. MiMedx reported a 71% fall in wound sales in the third quarter of 2026, which is the main outside input to the stock portion. Sanara's price also reflects how the market judges FTC review of medical-device and regenerative-product deals. Broad equity moves matter less than the FTC process and MiMedx's share price.